CEO Chris Cargill talks to Scrip about Sosei Heptares’ new identity as Nxera, the ups and downs of being big pharma’s go-to small-molecule drug hunter and its move into commercialization in Japan.
First set up in 1990 by former Genentech executive Shinichi Tamura, Sosei, now known as Nxera, was founded with the goal of creating Japan’s “first global biotech champion.”
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.
With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
